SEC Form 4 · accession 0001209191-19-007574
PROTEOSTASIS THERAPEUTICS, INC. · PTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benito Munoz
Officer — Chief Scientific Officer
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 8:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001445283
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 1, 2019 | M | 24,953 | — | A | 24,953 | D | |
| Common StockF2,F3 | Feb 4, 2019 | S | 9,514 | $2.9907 | D | 15,439 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F4 | — | Feb 1, 2019 | M | 24,953 | D | — | — | Common Stock | 24,953 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of PTI common stock.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and were made in order to pay the tax liability arising from the vesting of restricted stock units.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.96 to $3.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The restricted stock units vested in full on February 1, 2019.